WO2024047241A1 - Treatment of fasciolosis - Google Patents
Treatment of fasciolosis Download PDFInfo
- Publication number
- WO2024047241A1 WO2024047241A1 PCT/EP2023/074068 EP2023074068W WO2024047241A1 WO 2024047241 A1 WO2024047241 A1 WO 2024047241A1 EP 2023074068 W EP2023074068 W EP 2023074068W WO 2024047241 A1 WO2024047241 A1 WO 2024047241A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- fasciolosis
- use according
- mammal
- compounds
- Prior art date
Links
- 208000006275 fascioliasis Diseases 0.000 title claims abstract description 68
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 241000124008 Mammalia Species 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 241001494479 Pecora Species 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 14
- 241000242541 Trematoda Species 0.000 claims description 14
- -1 (S)- fluralaner Chemical compound 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 claims description 7
- 229960004498 fluralaner Drugs 0.000 claims description 7
- OXDDDHGGRFRLEE-UHFFFAOYSA-N 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)NCC(=O)NCC(F)(F)F)=CC=C1C(C1)=NOC1(C(F)(F)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 OXDDDHGGRFRLEE-UHFFFAOYSA-N 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- HDKWFBCPLKNOCK-SFHVURJKSA-N 3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5s)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)NCC(=O)NCC(F)(F)F)=C(C)C=C1C1=NO[C@](C(F)(F)F)(C=2C=C(Cl)C(Cl)=C(Cl)C=2)C1 HDKWFBCPLKNOCK-SFHVURJKSA-N 0.000 claims description 5
- FLEFKKUZMDEUIP-QFIPXVFZSA-N 1-[6-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-QFIPXVFZSA-N 0.000 claims description 4
- 229960000982 afoxolaner Drugs 0.000 claims description 4
- TVAJZOVLQZNNCJ-UHFFFAOYSA-N 2-chloro-n-(1-cyanocyclopropyl)-5-[1-[2-methyl-5-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)pyrazol-3-yl]pyrazol-4-yl]benzamide Chemical compound CN1N=C(C(F)(F)C(F)(F)F)C(C(F)(F)F)=C1N1N=CC(C=2C=C(C(Cl)=CC=2)C(=O)NC2(CC2)C#N)=C1 TVAJZOVLQZNNCJ-UHFFFAOYSA-N 0.000 claims description 3
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 3
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229950002303 lotilaner Drugs 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229960005393 sarolaner Drugs 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 229950007146 tigolaner Drugs 0.000 claims description 3
- 241000242711 Fasciola hepatica Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 244000045947 parasite Species 0.000 description 9
- 241000282849 Ruminantia Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000935974 Paralichthys dentatus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 6
- 210000000013 bile duct Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 5
- 206010061217 Infestation Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229960000323 triclabendazole Drugs 0.000 description 5
- 241000204939 Fasciola gigantica Species 0.000 description 4
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 description 4
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 4
- 229960002669 albendazole Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229950004178 closantel Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000005660 Abamectin Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- SGKGVABHDAQAJO-UHFFFAOYSA-N nitroxynil Chemical compound OC1=C(I)C=C(C#N)C=C1[N+]([O-])=O SGKGVABHDAQAJO-UHFFFAOYSA-N 0.000 description 3
- 229950003126 oxyclozanide Drugs 0.000 description 3
- JYWIYHUXVMAGLG-UHFFFAOYSA-N oxyclozanide Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl JYWIYHUXVMAGLG-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OFGKIOOXISVXEC-NRFANRHFSA-N 1-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-(2,2-difluoroethylamino)-2-oxoethyl]-5,6-dihydro-4h-cyclopenta[c]thiophene-3-carboxamide Chemical compound C1([C@]2(ON=C(C2)C=2SC(=C3CCCC3=2)C(=O)NCC(=O)NCC(F)F)C(F)(F)F)=CC(Cl)=C(F)C(Cl)=C1 OFGKIOOXISVXEC-NRFANRHFSA-N 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 2
- QOVTVIYTBRHADL-UHFFFAOYSA-N 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide Chemical compound NC1=CC(C(Cl)=C(Cl)Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O QOVTVIYTBRHADL-UHFFFAOYSA-N 0.000 description 2
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 2
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000283968 Syncerus caffer Species 0.000 description 2
- 241000869417 Trematodes Species 0.000 description 2
- 241001416177 Vicugna pacos Species 0.000 description 2
- 229950008167 abamectin Drugs 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940124339 anthelmintic agent Drugs 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- YBQWEUNEYYXYOI-UHFFFAOYSA-N arsenamide Chemical compound NC(=O)C1=CC=C([As](SCC(O)=O)SCC(O)=O)C=C1 YBQWEUNEYYXYOI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000275 clorsulon Drugs 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- DYVLXWPZFQQUIU-WGNDVSEMSA-N derquantel Chemical compound O1C(C)(C)C=COC2=C1C=CC1=C2NC[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 DYVLXWPZFQQUIU-WGNDVSEMSA-N 0.000 description 2
- 229950004278 derquantel Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 244000078703 ectoparasite Species 0.000 description 2
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 2
- 229960002346 eprinomectin Drugs 0.000 description 2
- OXDDDHGGRFRLEE-QHCPKHFHSA-N esafoxolaner Chemical compound C1([C@]2(ON=C(C2)C2=CC=C(C3=CC=CC=C32)C(=O)NCC(=O)NCC(F)(F)F)C(F)(F)F)=CC(Cl)=CC(C(F)(F)F)=C1 OXDDDHGGRFRLEE-QHCPKHFHSA-N 0.000 description 2
- 229940121557 esafoxolaner Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005473 fenbendazole Drugs 0.000 description 2
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 2
- 230000000047 flukicidal effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002547 isoxazolines Chemical class 0.000 description 2
- 229960002418 ivermectin Drugs 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- WTERNLDOAPYGJD-SFHVURJKSA-N monepantel Chemical compound C([C@@](C)(NC(=O)C=1C=CC(SC(F)(F)F)=CC=1)C#N)OC1=CC(C#N)=CC=C1C(F)(F)F WTERNLDOAPYGJD-SFHVURJKSA-N 0.000 description 2
- 229950003439 monepantel Drugs 0.000 description 2
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 2
- 229960004816 moxidectin Drugs 0.000 description 2
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 2
- 229960004454 oxfendazole Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- FAWYSFCVOGQMFE-UHFFFAOYSA-N 1h-benzimidazole;1,3-thiazole Chemical class C1=CSC=N1.C1=CC=C2NC=NC2=C1 FAWYSFCVOGQMFE-UHFFFAOYSA-N 0.000 description 1
- BHFLSZOGGDDWQM-UHFFFAOYSA-N 1h-benzimidazole;carbamic acid Chemical class NC(O)=O.C1=CC=C2NC=NC2=C1 BHFLSZOGGDDWQM-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- WCBVUETZRWGIJQ-UHFFFAOYSA-N 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid Chemical compound CCCSC1=CC=C([N+]([O-])=O)C(NC(NC(=O)OC)=NCCS(O)(=O)=O)=C1 WCBVUETZRWGIJQ-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- HDKWFBCPLKNOCK-UHFFFAOYSA-N 3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)NCC(=O)NCC(F)(F)F)=C(C)C=C1C1=NOC(C(F)(F)F)(C=2C=C(Cl)C(Cl)=C(Cl)C=2)C1 HDKWFBCPLKNOCK-UHFFFAOYSA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- BPFUIWLQXNPZHI-UHFFFAOYSA-N 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-N-[(methoxyamino)methylidene]-2-methylbenzamide Chemical compound C1=C(C)C(C(=O)N\C=N/OC)=CC=C1C1=NOC(C(F)(F)F)(C=2C=C(Cl)C=C(Cl)C=2)C1 BPFUIWLQXNPZHI-UHFFFAOYSA-N 0.000 description 1
- FZSKGXIWZNECQR-UHFFFAOYSA-N 6H-cyclopenta[c]thiophene-3-carboxamide Chemical compound C=1(SC=C2C=1C=CC2)C(=O)N FZSKGXIWZNECQR-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 description 1
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RSIJAQZNHHXEJZ-UHFFFAOYSA-N Sempervirol Natural products CC1(C)CCCC2(C)C(C=C(C(=C3)O)C(C)C)=C3CCC21 RSIJAQZNHHXEJZ-UHFFFAOYSA-N 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 241001414987 Strepsiptera Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 229950004370 amidantel Drugs 0.000 description 1
- 150000008361 aminoacetonitriles Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VJDZMZAZDFKMSV-UHFFFAOYSA-N benzene-1,2-disulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1S(N)(=O)=O VJDZMZAZDFKMSV-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960003475 cambendazole Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MKFMTNNOZQXQBP-UVTDQMKNSA-N chembl2105966 Chemical compound COCC(=O)NC1=CC=C(\N=C(\C)N(C)C)C=C1 MKFMTNNOZQXQBP-UVTDQMKNSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical compound C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 description 1
- 229960001575 emodepside Drugs 0.000 description 1
- 108010056417 emodepside Proteins 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005362 epsiprantel Drugs 0.000 description 1
- LGUDKOQUWIHXOV-UHFFFAOYSA-N epsiprantel Chemical compound C1C(C2=CC=CC=C2CCC2)N2C(=O)CN1C(=O)C1CCCCC1 LGUDKOQUWIHXOV-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003549 fasciolicidal effect Effects 0.000 description 1
- 229960005282 febantel Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 229960004500 flubendazole Drugs 0.000 description 1
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000016332 liver symptom Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 1
- 229940099245 milbemycin oxime Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229940125259 mivorilaner Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005121 morantel Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- XOIOGKHKNQYULW-UHFFFAOYSA-N n'-[4-[[4-[[4-[1-(dimethylamino)ethylideneamino]phenyl]iminomethyl]phenyl]methylideneamino]phenyl]-n,n-dimethylethanimidamide Chemical compound C1=CC(N=C(C)N(C)C)=CC=C1N=CC(C=C1)=CC=C1C=NC1=CC=C(N=C(C)N(C)C)C=C1 XOIOGKHKNQYULW-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000037971 neglected tropical disease Diseases 0.000 description 1
- 229950006716 netobimin Drugs 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- SVMGVZLUIWGYPH-UHFFFAOYSA-N nitroscanate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(N=C=S)C=C1 SVMGVZLUIWGYPH-UHFFFAOYSA-N 0.000 description 1
- 229950009909 nitroscanate Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960002762 oxibendazole Drugs 0.000 description 1
- 229930188716 paraherquamide Natural products 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229950007337 parbendazole Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 1
- 229960005134 pyrantel Drugs 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- CCSONKKTCMHYFI-UHFFFAOYSA-N pyrido[3,4-f]quinoxaline Chemical class C1=NC=C2C3=NC=CN=C3C=CC2=C1 CCSONKKTCMHYFI-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229950002980 rafoxanide Drugs 0.000 description 1
- NEMNPWINWMHUMR-UHFFFAOYSA-N rafoxanide Chemical compound OC1=C(I)C=C(I)C=C1C(=O)NC(C=C1Cl)=CC=C1OC1=CC=C(Cl)C=C1 NEMNPWINWMHUMR-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Definitions
- the present invention relates to compounds and compositions for treating fasciolosis in a mammal.
- Fasciolosis is an important zoonotic disease that is responsible for a significant loss in food resource and animal productivity. Fasciolosis is a disease of both veterinary and public health importance, infecting over 600 million animals. The infection causes massive loss through liver condemnation, reduced production of milk, meat, and wool, veterinary care, metabolic disease as well as mortality
- Fasciolosis is caused by the trematode parasite Fasciola spp. Fasciola hepatica and Fasciola gigantica are the two main species responsible for most fasciolosis cases in mammals. Fasciola hepatica is cosmopolitan in nature because of its ability to infect a variety of species, while Fasciola gigantica is more common in tropical countries, though both species are found in Africa and Asia.
- Fasciolosis can result from the migration of large numbers of immature fluke larvae through the liver, from the presence of adult flukes in the bile ducts, or both. Fasciolosis occurs in three main clinical forms - acute, subacute and chronic fasciolosis. Which form occurs depends on the numbers of infective metacercariae ingested and the period over which they are ingested.
- fasciolosis The primary impact of fasciolosis is on farmed ruminants, however, they are not selective regarding the final host and successfully infect a wide range of mammals, including humans. Among the farmed ruminants, fasciolosis may cause annual economic losses of several billions of dollars world-wide.
- Mature F. hepatica are large, leaf-shaped trematodes; about 3 to 5 cm in length and 1 cm in width. Both the immature and the mature stages of the parasite feed by secreting enzymes, most notably cysteine proteases, which break down blood and the liver tissue. The parasites irritate the walls of the bile ducts causing hyperplasia of the bile duct epithelium.
- triclabendazole (TCBZ)
- TABZ triclabendazole
- immature stages i.e. early immature larvae (1 to 6 weeks old) and immature larvae (6 to 9 weeks old).
- it is the only flukicide effective against all early immature liver fluke larvae.
- Isoxazoline compounds are known in the art and these compounds are described, for example, in US patent application US 2007/0066617, and international patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2009/080250, WO 2010/070068 and WO 2010/079077.
- This class of compounds is known to possess excellent activity against ectoparasites i.e. parasites that have their permanent or temporary habitat on the external surface of animals, such as parasitic insects and acarids such as ticks and fleas and mites.
- ectoparasites i.e. parasites that have their permanent or temporary habitat on the external surface of animals, such as parasitic insects and acarids such as ticks and fleas and mites.
- the Applicant has addressed the problems of the prior art by identifying compounds that are effective at treating fasciolosis.
- the current invention provides a compound of Formula (I)
- R 1 - R 5 is H, F, Cl or CF 3
- X is O or S, preferably O
- Y is selected from
- - denotes the bond to the carbonyl group for use in the treatment of fasciolosis of mammals.
- Another aspect of the current invention is a composition comprising such compound and a pharmaceutically acceptable carrier for use in the treatment of fasciolosis of mammals.
- the compound for use according to the current invention is tigolaner.
- Fasciolosis refers to a clinical or subclinical disease of mammals in connection with an infection of a mammal with Fasciola hepatica or Fasciola gigantica.
- the fasciolosis is due to liver fluke infestation by immature or early immature stage and symptoms caused by such infestation.
- Fascioliosis ranges in severity from a devastating disease in sheep, and pseudo-ruminants such as alpacas, and llamas to a subclinical infection that is more common in cattle.
- Acute disease occurs 2-6 weeks after the ingestion of large numbers of metacercaria over a short period.
- acute fascioliosis occurs seasonally and is manifest by a distended, painful abdomen; anemia; and sudden death.
- the acute syndrome can be complicated by concurrent infections with Clostridium novyi, resulting in black disease (clostridial necrotic hepatitis).
- subacute disease In subacute disease, large numbers of metacercaria are ingested over longer periods of time; survival is longer (7-10 weeks), even in cases with extensive hepatic damage, but deaths occur because of hemorrhage and anemia.
- Subacute fasciolosis is characterized by jaundice, some ill thrift and anemia. The burrowing fluke stages causes extensive tissue damage, leading to hemorrhaging and liver damage. The outcome is severe anemia, liver failure and death.
- Chronic fascioliosis can occur in any season, but it manifests primarily in late fall and winter. It occurs as a result of ingesting moderate numbers of metacercariae over much longer periods of time.
- Chronic fasciolosis is the most common form of liver fluke infection in sheep, goats and cattle - and particularly in more resistant hosts, such as horses and pigs. It occurs when the parasites reach the bile ducts in the liver. The fluke ingests blood, which produces severe anemia and chronic inflammation and enlargement of the bile ducts. The clinical signs develop slowly. The animals become increasingly anemic, appetite is lowered, the mucous membranes of the mouth and eyes become pale, and some animals develop oedema under the jaw ('bottle jaw'). Affected animals are reluctant to travel.
- Significant production losses caused by (especially subcl inical) fasciolosis in livestock include reduced production and quality of wool, reduced lambing percentages, poor growth rate of lambs and/or increased costs for replacement stock in sheep; reduced calving percentages, poor growth rate of calves and/or increased costs for replacement stock in cattle; reduced production and quality of milk in dairy cattle and lower growth rates and lower feed conversion rates in fattening cattle.
- live fluke infection refers to infestation of a mammal with Fasciola hepatica or Fasciola gigantica parasites. Unless otherwise indicated the term includes infestation or infection by flukes at any stage of maturity and mixtures of stages of maturity.
- Fasciola spp. can be categorized into three stages, early immature, immature, and mature (commonly termed the adult stage).
- the fasciolosis is due to liver fluke infection by early immature stage liver fluke i.e., by early immature larvae (1 to 6 weeks old).
- the fasciolosis is due to liver fluke infection by immature stage liver fluke i.e., by immature larvae (6 to 9 weeks old).
- the fasciolosis is due to liver fluke infection by mature stage liver fluke i.e., by mature flukes (>9 weeks old).
- the compound for use according to the invention is effective against all immature liver fluke larvae.
- the compound for use according to the invention is effective against all stages of liver flukes.
- mammal refers to warm-blooded vertebrate animals having hair or fur and secrete milk by the females for the nourishment of the young and includes humans.
- mammals are ruminants, for example cattle, sheep, goats, bison, African buffalo, water buffalo, antelopes, deer, moose, elks, and giraffes.
- pseudo-ruminants for example, llamas and alpacas.
- mammal included in the term mammal are other susceptible animals such as horses, pigs and donkeys.
- mammals are understood to be sheep, goats, bison, African buffalo, water buffalo, and cattle. Even more particularly, mammals are sheep and cattle.
- the mammal is a ruminant.
- the mammal is selected from the group consisting of sheep and cattle.
- the ruminant is sheep.
- the ruminant is cattle.
- veterinary has the same definition as “pharmaceutical” but adapted to mammal animals (meaning non-human beings).
- a "veterinary drug” means a compound or mixture of compounds (conventionally together with inert formulation ingredients) , which is used, or is manufactured, sold or represented as suitable for use, in the diagnosis, treatment, control, eradication, mitigation or prevention of disease or abnormal physical or mental state or the symptoms thereof in an animal; or restoring, correcting, controlling, or modifying any physical, mental or organic function in an animal.
- 'treatment' refers to the administration of an effective amount of the compound as described for use in the invention to a mammal which has been diagnosed with and /or shows symptoms of fasciolosis of more or less severity.
- the skilled clinician can readily determine a mammal in need of the present treatment.
- the typical symptoms of acute, subactute and chronic fascilosis have been described earlier.
- the fasciolosis as cause of the symptoms can be detected by antibody testing, specifically ELISA testing, in particular of the blood and milk.
- the fasciolosis as cause of the symptoms by detection of the Fasciola spp. infection can also be diagnosed by examining fecal specimens, including by ELISA testing. Moreover, modeling based on season, rainfall, temperature, and other local conditions can be used to predict times when fasciolosis is more likely.
- fasciolosis is treated during autumn, winter, or early spring season.
- liver fluke stages present at this high-risk period.
- the compounds for use according to the invention are especially useful - in a situation wherein fasciolosis of the mammal- especially cattle or sheep- is due to an immature stage liver fluke infection and such infection is treated during autumn, winter, or early spring season.
- fasciolosis of the mammal- especially cattle or sheep- is due to an immature stage liver fluke infection and such infection is treated during autumn, winter, or early spring season.
- This provides a very useful treatment option to treat fasciolosis and the symptoms of such disease during the season with especially high risk of damage to the infected animal. During such season the immature stages of liver fluke are predominantly.
- the compound for use according to the current invention is used for treatment during summer, sometimes called mid-season treatment in which predominantly adult stages of liver flukes and symptoms caused by this infection are present in the treated mammal. In Australia this is done during the months January/ February.
- an "effective amount” for use in the invention is the amount, therapeutic dose, or quantity of a compound as described herein, that is required for a significant reduction of the parasites infesting such animal and when administered to a mammal for treating a disease, is sufficient to ameliorate or prevent the symptoms of acute, subacute or chronical fasciolosis to effect such treatment for the disease.
- the "therapeutically effective amount" for the treatment of the different forms of fasciolosis will vary depending on the specific compound, the veterinary drug form, the age, weight, etc., of the mammal to be treated.
- Compounds of Formula (I) for use in the current invention are:
- X is O or S, preferably O
- Y is selected from wherein denotes the bond to the isoxazoline or isothiazoline
- the compound is 4-[5- (3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-/ ⁇ /-[(2,2,2-trifluoro- ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3). This compound is also known as fluralaner.
- the compound is 4-[5- [3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2- trifluoroethyl)amino]ethyl]-l-naphthalene-carboxamide (CAS RN 1093861-60-9).
- This compound is also known as a 4-[5-(5-chloro-a,a,a-trifluoro-m-tolyl)-4,5-dihydro-5-(trifluoromethyl)-l,2-oxazol- 3yl]-/V-[2-oxo-2-[(2,2,2-trifluoroethylamino]ethyl]naphthalene-l-or afoxolaner.
- Afoxolaner is for example disclosed in WO 2007/079162.
- the isoxazoline compound is Esafoxolaner.
- the compound is l-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H- spiro[azetidine-3,l'-isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one, preferably l-(5'-((5S)-(5- (3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3, - isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one (CAS RN: 1398609-39-6). This compound is known as sarolaner.
- the compound is 3- methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-[5-(3,4,5-trichlorophenyl)-5- (trifluoromethyl)-4,5-dihydroisoxazol-3-yl]thiophene-2-carboxamide, preferably methyl-N-(2-oxo-2- ((2,2,2-trifluoroethyl)amino)ethyl)-5-[(5S)-5(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5- dihydroisoxazol-3-yl]thiophene-2-carboxamide (CAS RN: 1369852-71-0). This compound is known as lotilaner.
- a compound used as alternative is 2-chloro-/V-(l-cyanocyclopropyl)-5-[l-[2-methyl-5-(l,l,2,2,2-pentafluoroethyl)-4- (trifluoromethyl)pyrazol-3-yl]pyrazol-4-yl]benzamide (CAS RN 1621436) This compound is known as tigolaner.
- the compound is 4H- Cyclopenta[c]thiophene-l-carboxamide, 3-[(5S)-5-(3,5-dichloro-4- fluorophenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl]-N-[2-[(2,2- difluoroethyl)amino]-2-oxoethyl]-5,6-dihydro- (CAS 1414642-93-5). This compound is known as mivorilaner.
- the compound of Formula (I) is (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxy- imino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
- the compound is 4-[5- (3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl) benzamide (CAS RN 1164267-94-0) that was disclosed in WO 2009/0080250.
- the compound is 5-[5- (3,5-dDichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2- trifluoroethyl) amino] ethyl]- 2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO 2010/070068.
- the compound of Formula (I) is selected from fluralaner (including (S) fluralaner), afoxolaner (including esafoxolaner), sarolaner, or lotilaner.
- fluralaner corresponding to 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5- dihydroisoxazol-3-yl]-2-methyl-/ ⁇ /-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide
- systemic insecticide and/or acaricide a) which is represented by Formula (II)
- the compounds for use according to the current invention may exist in various isomeric forms.
- a reference to a compound always includes all possible isomeric forms of such a compound.
- a compound structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the compound, as well as compositions comprising fewer than all the possible conformational isomers.
- Compounds of Formula (I) can be prepared according to one or other of the processes described e.g., in patent applications US 2007/0066617, WO 2007/079162, WO 2009/002809, WO 2009/080250, WO 2010/070068, WO 2010/079077, WO 2011/075591 and WO 2011/124998 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis.
- composition for use according to the invention comprising more than one pharmaceutically active ingredient, i.e. wherein the composition for oral administration comprises another active pharmaceutical ingredient.
- the term “comprise,” or variations thereof such as “comprises” or “comprising,” are to be read to indicate the inclusion of any recited integer (e.g., a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g., features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
- combination with as well as “combination” and “synergistic combination” as used herein are taken to mean that a compound different from a compound of Formula (I) or another compound of Formula (I) is administered prior to, during, or after the administration of an compound of Formula (I). That is, in these are administered either sequentially or simultaneously to the mammal.
- the combination is with a compound different from a compound of Formula (I).
- sequentially administration means administration of within three days of administration of the other.
- the compounds for use of the current invention are administered together with the combination compound within a day of each other and even more typically on the same day.
- Sequential administration also means administration of such compounds within an hour, or even minutes, of administration of the othe compound.
- Simultaneous administration includes preferably the presence of such compounds in the same veterinary product.
- active ingredients which may include, without limitation antiparasitics such as endoparasiticides (including anthelmintics) and ecto-parasiticides, hormones and/or derivatives thereof, anti-inflammatory compounds and minerals and vitamins.
- antiparasitics such as endoparasiticides (including anthelmintics) and ecto-parasiticides, hormones and/or derivatives thereof, anti-inflammatory compounds and minerals and vitamins.
- a combination with selenium especially as sodium selenate.
- the active ingredients are preferably antiparasitics, more preferably endoparasiticides, preferably anthelmintics and are preferably selected from the group consisting of avermectins (e.g., ivermectin, doramectin, abamectin, eprinomectin); milbemycins (moxidectin and milbemycin oxime); probenzimidazoles (e.g., febantel, netobimin, and thiophanate); benzimidazole derivatives, such as a thiazole benzimidazole derivatives (e.g., thiabendazole and cambendazole), carbamate benzimidazole derivatives (e.g., fenbendazole, albendazole (oxide), mebendazole, oxfendazole, parbendazole, oxibendazole, flubendazole, and triclabendazole); imidazothi
- ivermectin eprinomectin
- moxidectin levamisole
- fenbendazole abamectin, monepantel, derquantel, oxfendazole, albendazole, closantel and combinations thereof.
- An effective amount of the compound for use according to the current invention is administered to the mammal orally or parenterally.
- an effective amount is administered orally to the mammal.
- an effective amount is administered parenterally to the mammal.
- the compounds are administered to an animal in need thereof in the form of a pharmaceutical or veterinary composition.
- compositions for oral administration include components conventionally used in the art of formulation and may therefore be processed in a known manner to give, for example, solutions, emulsions, soluble powders, powder mixtures, granules or microencapsulation in polymeric substances.
- Such formulations, preparations or compositions optionally include a solid or liquid adjuvant, and are produced in a manner well-known in the art, for example by intimately mixing and/or grinding the active ingredients with the adjuvants, for example with solvents, solid carriers, etc.
- Oral administration can also be accomplished by drench, gavage, tablet, capsule, or in feed.
- compositions are known to be suitable for oral administration to animals, but they vary for the different animal species.
- Oral administration can be accomplished by conventional dosage forms, such as e.g. drench, gavage, tablet, capsule, or in feed.
- Drenching means that a liquid, potentially slightly viscous pharmaceutical composition comprising the active pharmaceutical ingredient and excipients is applied via the mouth with a specific drenching gun that dispenses the composition into the sheep's throat.
- Oral drench compositions are in general solutions or suspensions and generally not more than 20 ml, preferably not more than 15 ml of such drench are applied per sheep.
- a concentrated solution is used to administer the compound for use according to the invention via drench application to sheep.
- a suspension formulation is used for the drench application.
- Excipients may comprise conventional non active pharmaceutically and veterinarily acceptable components or excipients e.g. fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, viscosity enhancer, surfactants, stabilizers, such as antioxidants.
- excipients e.g. fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, viscosity enhancer, surfactants, stabilizers, such as antioxidants.
- the pharmaceutical excipients are excipients with which the person skilled in the art is familiar, such as those which are described in the European Pharmacopoeia.
- Parenteral administration includes injectable administration, especially subcutaneous administration. This is a preferred administration route for larger ruminant animals such as cattle.
- compositions are known to be suitable for subcutaneous injection administration to animals, generally liquid compositions such as solutions or suspensions of the compounds of Formula (I) using pharmaceutically acceptable solvents and/or suspending agents.
- the composition for subcutaneous administration can be either a liquid solution or suspension or a semi-solid or solid composition e.g., an implant.
- a solution is a mixture of two or more components that form a single phase that is homogeneous down to the molecular level.
- a suspension consists of insoluble solid particles dispersed in a liquid medium, with the solid particles accounting for about 0.5% to about 30% of the suspension.
- the liquid may be aqueous, oily, or both.
- a suitable injectable solution of compounds is a pharmaceutical composition that comprises an isoxazoline compound, and a pharmaceutically acceptable carrier comprising 2 pyrrolidone, PEG and propylene glycol.
- a pharmaceutically acceptable carrier comprising 2 pyrrolidone, PEG and propylene glycol.
- An alternative is an aqueous suspension.
- the amounts of each of the components in the final product may be varied considerably, depending upon the nature of the pharmaceutically active ingredients, the weight and condition of the subject treated, and the unit dosage desired.
- the effective dose of the compound of formula (I) is between 0.5 mg/kg bodyweight and 50 mg/kg bodyweight.
- Those of ordinary skill in the art will be able to adjust dosage amounts for particular compounds in the composition in light of the teachings of this disclosure and the available information about such compounds.
- the product according to the current invention conventionally further comprises physiologically acceptable formulation excipients known in the art e.g., as described in "Gennaro, Remington: The Science and Practice of Pharmacy” (20th Edition, 2000) incorporated by reference herein.
- ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and non-toxic in the amounts employed and must be compatible with the pharmaceutically active ingredients.
- the veterinary composition for use according to the invention can be in one embodiment mixed with an existing commercial product before administration to an animal.
- the composition includes a combination of an effective amount of a compound for use according to the current invention and another compound (or a commercial product with such compound) that controls a different parasite infestation, e.g., against parasitic helminths or alternatively ectoparasites, especially fly strike.
- a different parasite infestation e.g., against parasitic helminths or alternatively ectoparasites, especially fly strike.
- two compounds of Formula (I) as described above are included in a composition that control different parasites.
- the viability detection of Fasciola hepatica NEJs is based on qualitative microscopic evaluation of motility and phenotype and additionally measuring propidium iodide to make use of the differential uptake of fluorophores (such as propidium iodide) by living organisms.
- NEJs were prepared according to Edwards et al. [1], Approximately 12 NEJs/compound were cultivated. NEJ/compound co-cultures were placed at 37°C in a humidified atmosphere containing 5% CO2. NEJ/compound co-cultures were incubated for a total of 72 hrs. At 24h, an assessment of the gross phenotype was made for all NEJ/compound co-cultures and bright field images were captured. At 72h both phenotype and motility were quantified in comparison to live DMSO controls based on a microscopic scoring method detailed in [1] as well as summarised in Table 1 below.
- PI Propidium Iodide
Abstract
The present invention relates to compounds and compositions of Formula (I) for treating a fasciolosis in a mammal.
Description
Treatment of Fasciolosis
Field of the Invention
The present invention relates to compounds and compositions for treating fasciolosis in a mammal.
Background of the Invention
Fasciolosis is an important zoonotic disease that is responsible for a significant loss in food resource and animal productivity. Fasciolosis is a disease of both veterinary and public health importance, infecting over 600 million animals. The infection causes massive loss through liver condemnation, reduced production of milk, meat, and wool, veterinary care, metabolic disease as well as mortality
Fasciolosis is caused by the trematode parasite Fasciola spp. Fasciola hepatica and Fasciola gigantica are the two main species responsible for most fasciolosis cases in mammals. Fasciola hepatica is cosmopolitan in nature because of its ability to infect a variety of species, while Fasciola gigantica is more common in tropical countries, though both species are found in Africa and Asia.
Fasciolosis can result from the migration of large numbers of immature fluke larvae through the liver, from the presence of adult flukes in the bile ducts, or both. Fasciolosis occurs in three main clinical forms - acute, subacute and chronic fasciolosis. Which form occurs depends on the numbers of infective metacercariae ingested and the period over which they are ingested.
The primary impact of fasciolosis is on farmed ruminants, however, they are not selective regarding the final host and successfully infect a wide range of mammals, including humans. Among the farmed ruminants, fasciolosis may cause annual economic losses of several billions of dollars world-wide.
Mature F. hepatica are large, leaf-shaped trematodes; about 3 to 5 cm in length and 1 cm in width. Both the immature and the mature stages of the parasite feed by secreting enzymes, most notably cysteine proteases, which break down blood and the liver tissue. The parasites irritate the walls of the bile ducts causing hyperplasia of the bile duct epithelium.
There is a range of products that can be used to treat mammals against fasciolosis, especially ruminants such as sheep and cattle. When recommending treatment plans it is important to use drugs that target the stage of Fasciola spp. most likely to be present within the diseased animal at the time, to help reduce selection pressure.
From the available flukicidal compounds only one compound, triclabendazole (TCBZ), is effective against mature stages of the common liver fluke (Fasciola hepatica) as well as all immature stages, i.e. early immature larvae (1 to 6 weeks old) and immature larvae (6 to 9 weeks old). In fact, it is the only flukicide effective against all early immature liver fluke larvae.
However, resistance to flukicides can occur with repeated and frequent use, alternatives should be used wherever possible, particularly in late winter and spring, to reduce potential for the development of TCBZ-resistance.
Other drugs for treating Fosc/o/o-infected livestock are albendazole, closantel, nitroxynil and oxyclozanide. However, all of them are only effective against the mature flukes and not against the immature stages, such as early immature larvae (1 to 6 weeks old) and immature larvae (6 to 9 weeks old) . Closantel is partially effective against 3-8 weeks old flukes and fully effective against mature flukes; nitroxynil is effective against fluke from 8 weeks post infection and clorsulon, oxyclozanide and albendazole are effective only against mature flukes.
Consequently, current treatment options suffer from the ineffectiveness of most compounds against immature flukes during the migratory phase, the phase in which the most severe damage occurs to liver tissue when migrating towards the bile ducts.
The upcoming resistance to triclabendazole and other flukicidal compounds and lack of effective substitutes creates a pressing need in the field for alternative treatment options.
It is an object of this invention to overcome at least one of the above-referenced problems.
Isoxazoline compounds are known in the art and these compounds are described, for example, in US patent application US 2007/0066617, and international patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2009/080250, WO 2010/070068 and WO 2010/079077.
This class of compounds is known to possess excellent activity against ectoparasites i.e. parasites that have their permanent or temporary habitat on the external surface of animals, such as parasitic insects and acarids such as ticks and fleas and mites.
However, efficacy of isoxazoline compounds to treat fasciolosis has not been reported in prior art.
Summary of the Invention
The Applicant has addressed the problems of the prior art by identifying compounds that are effective at treating fasciolosis.
Formula (I)
R1 - R5 is H, F, Cl or CF3
X is O or S, preferably O
Y is selected from
- denotes the bond to the carbonyl group for use in the treatment of fasciolosis of mammals. Another aspect of the current invention is a composition comprising such compound and a pharmaceutically acceptable carrier for use in the treatment of fasciolosis of mammals.
In an alternative embodiment the compound for use according to the current invention is tigolaner.
Detailed description of the Invention
The current inventors found that compounds of Formula (I) are addressing the problem by providing a new fasciolosis treatment option.
It has been found that these compounds are particularly effective against immature liver flukes, that is fluke less than 9 weeks old, from mammals, whereas most commercially available fasciolicides are more effective against mature liver fluke, that is, fluke more than 9 weeks old, and indeed many such available compounds are barely effective against immature fluke.
Accordingly, use of the compounds of Formula (I) provides a valuable complementary treatment of fasciolosis when used alone or when used in conjunction with existing remedies.
Definitions and general preferences
When used herein and unless specifically indicated otherwise, the following terms are intended to have the following meanings in addition to any broader (or narrower) meanings the terms might enjoy in the art:
Unless otherwise required by context, the use herein of the singular is to be read to include the plural and vice versa. The term "a" or "an" used in relation to an entity is to be read to refer to any or more of that entity. As such, the terms "a" (or "an"), "any or more," and "at least one" are used interchangeably herein.
The term "fasciolosis" refers to a clinical or subclinical disease of mammals in connection with an infection of a mammal with Fasciola hepatica or Fasciola gigantica.
In one embodiment the fasciolosis is due to liver fluke infestation by immature or early immature stage and symptoms caused by such infestation.
Fascioliosis ranges in severity from a devastating disease in sheep, and pseudo-ruminants such as alpacas, and llamas to a subclinical infection that is more common in cattle.
Acute disease occurs 2-6 weeks after the ingestion of large numbers of metacercaria over a short period. In sheep, acute fascioliosis occurs seasonally and is manifest by a distended, painful abdomen; anemia; and sudden death. The acute syndrome can be complicated by concurrent infections with Clostridium novyi, resulting in black disease (clostridial necrotic hepatitis).
In subacute disease, large numbers of metacercaria are ingested over longer periods of time; survival is longer (7-10 weeks), even in cases with extensive hepatic damage, but deaths occur because of hemorrhage and anemia. Subacute fasciolosis is characterized by jaundice, some ill thrift and anemia. The burrowing fluke stages causes extensive tissue damage, leading to hemorrhaging and liver damage. The outcome is severe anemia, liver failure and death.
Chronic fascioliosis can occur in any season, but it manifests primarily in late fall and winter. It occurs as a result of ingesting moderate numbers of metacercariae over much longer periods of time.
Chronic fasciolosis is the most common form of liver fluke infection in sheep, goats and cattle - and particularly in more resistant hosts, such as horses and pigs. It occurs when the parasites reach the bile ducts in the liver. The fluke ingests blood, which produces severe anemia and chronic inflammation and enlargement of the bile ducts. The clinical signs develop slowly. The animals become increasingly anemic, appetite is lowered, the mucous membranes of the mouth and eyes
become pale, and some animals develop oedema under the jaw ('bottle jaw'). Affected animals are reluctant to travel.
Significant production losses caused by (especially subcl inical) fasciolosis in livestock, include reduced production and quality of wool, reduced lambing percentages, poor growth rate of lambs and/or increased costs for replacement stock in sheep; reduced calving percentages, poor growth rate of calves and/or increased costs for replacement stock in cattle; reduced production and quality of milk in dairy cattle and lower growth rates and lower feed conversion rates in fattening cattle.
The term "liver fluke infection" refers to infestation of a mammal with Fasciola hepatica or Fasciola gigantica parasites. Unless otherwise indicated the term includes infestation or infection by flukes at any stage of maturity and mixtures of stages of maturity.
The liver fluke has a complex life cycle. In its final host, Fasciola spp. can be categorized into three stages, early immature, immature, and mature (commonly termed the adult stage).
In one embodiment the fasciolosis is due to liver fluke infection by early immature stage liver fluke i.e., by early immature larvae (1 to 6 weeks old).
In another embodiment the fasciolosis is due to liver fluke infection by immature stage liver fluke i.e., by immature larvae (6 to 9 weeks old).
In another embodiment the fasciolosis is due to liver fluke infection by mature stage liver fluke i.e., by mature flukes (>9 weeks old).
In a preferred embodiment the compound for use according to the invention is effective against all immature liver fluke larvae.
In a more preferred embodiment, the compound for use according to the invention is effective against all stages of liver flukes.
The term "mammal" refers to warm-blooded vertebrate animals having hair or fur and secrete milk by the females for the nourishment of the young and includes humans. Particular mammals are ruminants, for example cattle, sheep, goats, bison, African buffalo, water buffalo, antelopes, deer, moose, elks, and giraffes.
Also, included in the term mammal are the so-called pseudo-ruminants, for example, llamas and alpacas.
Also, included in the term mammal are other susceptible animals such as horses, pigs and donkeys.
More particularly, mammals are understood to be sheep, goats, bison, African buffalo, water buffalo, and cattle. Even more particularly, mammals are sheep and cattle.
In one embodiment, the mammal is a ruminant. In a preferred embodiment, the mammal is selected from the group consisting of sheep and cattle. In one embodiment, the ruminant is sheep. In another embodiment, the ruminant is cattle.
According to the present invention the term "veterinary" has the same definition as "pharmaceutical" but adapted to mammal animals (meaning non-human beings).
More precisely, a "veterinary drug" (or medicine or composition) means a compound or mixture of compounds (conventionally together with inert formulation ingredients) , which is used, or is manufactured, sold or represented as suitable for use, in the diagnosis, treatment, control, eradication, mitigation or prevention of disease or abnormal physical or mental state or the
symptoms thereof in an animal; or restoring, correcting, controlling, or modifying any physical, mental or organic function in an animal.
The 'treatment', and similar terms such as 'treating' or 'treat' as used herein, refer to the administration of an effective amount of the compound as described for use in the invention to a mammal which has been diagnosed with and /or shows symptoms of fasciolosis of more or less severity.
The skilled clinician can readily determine a mammal in need of the present treatment. The typical symptoms of acute, subactute and chronic fascilosis have been described earlier. The fasciolosis as cause of the symptoms can be detected by antibody testing, specifically ELISA testing, in particular of the blood and milk.
The fasciolosis as cause of the symptoms by detection of the Fasciola spp. infection can also be diagnosed by examining fecal specimens, including by ELISA testing. Moreover, modeling based on season, rainfall, temperature, and other local conditions can be used to predict times when fasciolosis is more likely.
Preferably the fasciolosis is treated during autumn, winter, or early spring season.
Autumn is the time of year when grazing mammals are most likely to ingest large numbers of liver fluke metacercariae on the pasture. In Australia this is during the months April/ May. Once ingested liver fluke larvae migrate through the liver causing damage to the liver tissue and blood loss.
This high-risk situation extends (e.g., depending on the weather conditions) in many situations to the winter and early spring season. Therefore another treatment can be made during late winter/early spring., this is in Australia during the months August/ September.
Therefore, it is important that a compound allows effective treatment of the liver fluke stages present at this high-risk period. These are all stages of flukes, but especially important is the activity against immature larvae stages, especially early immature larvae that are present during this time.
In one embodiment the compounds for use according to the invention are especially useful - in a situation wherein fasciolosis of the mammal- especially cattle or sheep- is due to an immature stage liver fluke infection and such infection is treated during autumn, winter, or early spring season. This provides a very useful treatment option to treat fasciolosis and the symptoms of such disease during the season with especially high risk of damage to the infected animal. During such season the immature stages of liver fluke are predominantly.
In another embodiment the compound for use according to the current invention is used for treatment during summer, sometimes called mid-season treatment in which predominantly adult stages of liver flukes and symptoms caused by this infection are present in the treated mammal. In Australia this is done during the months January/ February.
What constitutes an "effective amount" for use in the invention is the amount, therapeutic dose, or quantity of a compound as described herein, that is required for a significant reduction of the parasites infesting such animal and when administered to a mammal for treating a disease, is sufficient to ameliorate or prevent the symptoms of acute, subacute or chronical fasciolosis to effect such treatment for the disease.
The "therapeutically effective amount" for the treatment of the different forms of fasciolosis will vary depending on the specific compound, the veterinary drug form, the age, weight, etc., of the mammal to be treated.
Compounds of Formula (I) for use in the current invention are:
X is O or S, preferably O
- denotes the bond to the carbonyl group.
In one preferred embodiment of the invention and/or embodiments thereof the compound is 4-[5- (3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-/\/-[(2,2,2-trifluoro- ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3). This compound is also known as fluralaner.
In one preferred embodiment of the invention and/or embodiments thereof the compound is 4-[5- [3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2- trifluoroethyl)amino]ethyl]-l-naphthalene-carboxamide (CAS RN 1093861-60-9). This compound is also known as a 4-[5-(5-chloro-a,a,a-trifluoro-m-tolyl)-4,5-dihydro-5-(trifluoromethyl)-l,2-oxazol- 3yl]-/V-[2-oxo-2-[(2,2,2-trifluoroethylamino]ethyl]naphthalene-l-or afoxolaner. Afoxolaner is for example disclosed in WO 2007/079162. In one embodiment the isoxazoline compound is Esafoxolaner.
In one especially preferred embodiment of the invention and/or embodiments thereof the compound is l-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H- spiro[azetidine-3,l'-isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one, preferably l-(5'-((5S)-(5- (3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3, - isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one (CAS RN: 1398609-39-6). This compound is known as sarolaner.
In one preferred embodiment of the invention and/or embodiments thereof the compound is 3- methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-[5-(3,4,5-trichlorophenyl)-5- (trifluoromethyl)-4,5-dihydroisoxazol-3-yl]thiophene-2-carboxamide, preferably methyl-N-(2-oxo-2- ((2,2,2-trifluoroethyl)amino)ethyl)-5-[(5S)-5(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5- dihydroisoxazol-3-yl]thiophene-2-carboxamide (CAS RN: 1369852-71-0). This compound is known as lotilaner.
In one preferred embodiment of the invention and/or embodiments thereof a compound used as alternative is 2-chloro-/V-(l-cyanocyclopropyl)-5-[l-[2-methyl-5-(l,l,2,2,2-pentafluoroethyl)-4- (trifluoromethyl)pyrazol-3-yl]pyrazol-4-yl]benzamide (CAS RN 1621436) This compound is known as tigolaner.
In one preferred embodiment of the invention and/or embodiments thereof the compound is 4H- Cyclopenta[c]thiophene-l-carboxamide, 3-[(5S)-5-(3,5-dichloro-4- fluorophenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl]-N-[2-[(2,2- difluoroethyl)amino]-2-oxoethyl]-5,6-dihydro- (CAS 1414642-93-5). This compound is known as mivorilaner.
In one preferred embodiment of the invention and/or embodiments thereof the compound of Formula (I) is (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxy- imino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
In one preferred embodiment of the invention and/or embodiments thereof the compound is 4-[5- (3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl) benzamide (CAS RN 1164267-94-0) that was disclosed in WO 2009/0080250.
In one preferred embodiment of the invention and/or embodiments thereof the compound is 5-[5- (3,5-dDichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2- trifluoroethyl) amino] ethyl]- 2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO 2010/070068.
In one preferred embodiment of the invention and/or embodiments thereof the compound of Formula (I) is selected from fluralaner (including (S) fluralaner), afoxolaner (including esafoxolaner), sarolaner, or lotilaner.
Especially preferred is fluralaner (corresponding to 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5- dihydroisoxazol-3-yl]-2-methyl-/\/-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide) as systemic insecticide and/or acaricide (a) which is represented by Formula (II)
Formula (II)
The compounds for use according to the current invention may exist in various isomeric forms. A reference to a compound always includes all possible isomeric forms of such a compound. Unless otherwise stated, a compound structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the compound, as well as compositions comprising fewer than all the possible conformational isomers.
Compounds of Formula (I) can be prepared according to one or other of the processes described e.g., in patent applications US 2007/0066617, WO 2007/079162, WO 2009/002809, WO 2009/080250, WO 2010/070068, WO 2010/079077, WO 2011/075591 and WO 2011/124998 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis.
For the chemical preparation, a person skilled in the art is regarded as having at her/his disposal, inter alia, the entire contents of "Chemical Abstracts" and of the documents cited therein.
This invention is also directed to composition for use according to the invention comprising more than one pharmaceutically active ingredient, i.e. wherein the composition for oral administration comprises another active pharmaceutical ingredient.
As used herein, the term "comprise," or variations thereof such as "comprises" or "comprising," are to be read to indicate the inclusion of any recited integer (e.g., a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g., features, element,
characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
Thus, as used herein the term "comprising" is inclusive or open ended and does not exclude additional, unrecited components or method/process steps.
The term "in combination with" as well as "combination" and "synergistic combination" as used herein are taken to mean that a compound different from a compound of Formula (I) or another compound of Formula (I) is administered prior to, during, or after the administration of an compound of Formula (I). That is, in these are administered either sequentially or simultaneously to the mammal. In a preferred embodiment the combination is with a compound different from a compound of Formula (I).
Typically, sequentially administration means administration of within three days of administration of the other.
More typically, the compounds for use of the current invention are administered together with the combination compound within a day of each other and even more typically on the same day.
Sequential administration also means administration of such compounds within an hour, or even minutes, of administration of the othe compound.
Simultaneous administration includes preferably the presence of such compounds in the same veterinary product.
Those of ordinary skill in the veterinary pharmaceutical arts will be entirely familiar with the identity of such active ingredients which may include, without limitation antiparasitics such as endoparasiticides (including anthelmintics) and ecto-parasiticides, hormones and/or derivatives thereof, anti-inflammatory compounds and minerals and vitamins.
Especially preferred is a combination with selenium, especially as sodium selenate.
The active ingredients are preferably antiparasitics, more preferably endoparasiticides, preferably anthelmintics and are preferably selected from the group consisting of avermectins (e.g., ivermectin, doramectin, abamectin, eprinomectin); milbemycins (moxidectin and milbemycin oxime); probenzimidazoles (e.g., febantel, netobimin, and thiophanate); benzimidazole derivatives, such as a thiazole benzimidazole derivatives (e.g., thiabendazole and cambendazole), carbamate benzimidazole derivatives (e.g., fenbendazole, albendazole (oxide), mebendazole, oxfendazole, parbendazole, oxibendazole, flubendazole, and triclabendazole); imidazothiazoles (e.g., levamisole and tetramisole); tetrahydropyrimidine (morantel and pyrantel), salicylanilides (e.g., closantel, oxyclozanide, rafoxanide, and niclosamide); nitrophenolic compounds (e.g., nitroxynil and nitroscanate); benzenedisulfonamides (e.g., clorsulon); pyrazinoisoquinolines (e.g., praziquantel and epsiprantel); heterocyclic compounds (e.g., piperazine, diethylcarbamazine, and phenothiazine); dichlorophen, arsenicals (e.g., thiacetarsamide, melorsamine, and arsenamide); cyclooctadepsipeptides (e.g., emodepside); paraherquamides (e.g. derquantel); and aminoacetonitrile compounds (e.g. monepantel); amidine compounds (e.g., amidantel and tribendimidin), including all pharmaceutically acceptable forms, such as salts, solvates or N-oxides.
Especially preferred are combinations with ivermectin, eprinomectin, moxidectin, levamisole, fenbendazole, abamectin, monepantel, derquantel, oxfendazole, albendazole, closantel and combinations thereof.
An effective amount of the compound for use according to the current invention is administered to the mammal orally or parenterally.
In one embodiment, an effective amount is administered orally to the mammal.
In one embodiment, an effective amount is administered parenterally to the mammal.
Generally, the compounds are administered to an animal in need thereof in the form of a pharmaceutical or veterinary composition.
Such compositions for oral administration include components conventionally used in the art of formulation and may therefore be processed in a known manner to give, for example, solutions, emulsions, soluble powders, powder mixtures, granules or microencapsulation in polymeric substances.
Such formulations, preparations or compositions optionally include a solid or liquid adjuvant, and are produced in a manner well-known in the art, for example by intimately mixing and/or grinding the active ingredients with the adjuvants, for example with solvents, solid carriers, etc.
Oral administration can also be accomplished by drench, gavage, tablet, capsule, or in feed.
A number of veterinary compositions are known to be suitable for oral administration to animals, but they vary for the different animal species. Oral administration can be accomplished by conventional dosage forms, such as e.g. drench, gavage, tablet, capsule, or in feed.
For sheep conventionally pharmaceutically active ingredients are administered orally as solids (e.g., tablets or boluses) or liquids, and via their feed or drinking water. In large sheep flocks the use of oral drenches is the most common oral dosage form.
Drenching means that a liquid, potentially slightly viscous pharmaceutical composition comprising the active pharmaceutical ingredient and excipients is applied via the mouth with a specific drenching gun that dispenses the composition into the sheep's throat.
Oral drench compositions are in general solutions or suspensions and generally not more than 20 ml, preferably not more than 15 ml of such drench are applied per sheep.
In one embodiment a concentrated solution is used to administer the compound for use according to the invention via drench application to sheep.
In another embodiment a suspension formulation is used for the drench application.
Excipients may comprise conventional non active pharmaceutically and veterinarily acceptable components or excipients e.g. fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, viscosity enhancer, surfactants, stabilizers, such as antioxidants.
The pharmaceutical excipients are excipients with which the person skilled in the art is familiar, such as those which are described in the European Pharmacopoeia.
Parenteral administration includes injectable administration, especially subcutaneous administration. This is a preferred administration route for larger ruminant animals such as cattle.
A number of veterinary compositions are known to be suitable for subcutaneous injection administration to animals, generally liquid compositions such as solutions or suspensions of the compounds of Formula (I) using pharmaceutically acceptable solvents and/or suspending agents.
The composition for subcutaneous administration can be either a liquid solution or suspension or a semi-solid or solid composition e.g., an implant.
A solution is a mixture of two or more components that form a single phase that is homogeneous down to the molecular level. A suspension consists of insoluble solid particles dispersed in a liquid medium, with the solid particles accounting for about 0.5% to about 30% of the suspension. The liquid may be aqueous, oily, or both.
An example for a suitable injectable solution of compounds, especially fluralaner, is a pharmaceutical composition that comprises an isoxazoline compound, and a pharmaceutically acceptable carrier comprising 2 pyrrolidone, PEG and propylene glycol. An alternative is an aqueous suspension.
The amounts of each of the components in the final product may be varied considerably, depending upon the nature of the pharmaceutically active ingredients, the weight and condition of the subject treated, and the unit dosage desired.
In general the effective dose of the compound of formula (I) is between 0.5 mg/kg bodyweight and 50 mg/kg bodyweight. Those of ordinary skill in the art will be able to adjust dosage amounts for particular compounds in the composition in light of the teachings of this disclosure and the available information about such compounds.
The product according to the current invention conventionally further comprises physiologically acceptable formulation excipients known in the art e.g., as described in "Gennaro, Remington: The Science and Practice of Pharmacy" (20th Edition, 2000) incorporated by reference herein.
All such ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and non-toxic in the amounts employed and must be compatible with the pharmaceutically active ingredients.
The veterinary composition for use according to the invention can be in one embodiment mixed with an existing commercial product before administration to an animal.
In one embodiment the composition includes a combination of an effective amount of a compound for use according to the current invention and another compound (or a commercial product with such compound) that controls a different parasite infestation, e.g., against parasitic helminths or alternatively ectoparasites, especially fly strike. In a specific embodiment two compounds of Formula (I) as described above are included in a composition that control different parasites.
Examples
The invention will now be described with reference to specific Examples. These are merely exemplary and for illustrative purposes only: they are not intended to be limiting in any way to the scope of the monopoly claimed or to the invention described.
Example
Material and Methods:
The effect of test compounds in a whole organism screen of Fasciola hepatica Newly Excysted
Juveniles (NEJs) was investigated along with DMSO (- control), triclabendazole (10pM, + control) and media) and their anti-flukicidal activity was assessed at both 24 and 72 hours.
Compounds were tested at lOpM and/or in declining concentrations of the test compound of 25pM, 12.5pM, 6.25pM, 3.125pM, and 1.562pM.
Table 1:
The viability detection of Fasciola hepatica NEJs is based on qualitative microscopic evaluation of motility and phenotype and additionally measuring propidium iodide to make use of the differential uptake of fluorophores (such as propidium iodide) by living organisms.
NEJs were prepared according to Edwards et al. [1], Approximately 12 NEJs/compound were cultivated. NEJ/compound co-cultures were placed at 37°C in a humidified atmosphere containing 5% CO2. NEJ/compound co-cultures were incubated for a total of 72 hrs. At 24h, an assessment of the gross phenotype was made for all NEJ/compound co-cultures and bright field images were captured. At 72h both phenotype and motility were quantified in comparison to live DMSO controls based on a microscopic scoring method detailed in [1] as well as summarised in Table 1 below.
Propidium Iodide (PI) was then added to the NEJ/compound co-cultures (to a final concentration of 2pg/mL) and these co-cultures were imaged under both Bright field and Texas Red settings.
Results:
The following compounds were found active against Fasciola hepatica NEJs during the viability assessment after 24 hours: 1, 2, 3, 4, 5, 6, 7 , 8, 9 and 10
The following compounds caused both a phenotype change and impaired motility significantly different to DMSO after 72 hours:l, 2,3, 4, 5, 6, 7 , 8, and 9 and 10.
The following compounds were found to cause a Propidium Iodide positivity > than 90%: 2, 3, 4, 5, 6, 7 , and 9.
Consequently, the following compounds displayed significant activity against juvenile stages of Fasciola hepatica: 1, 2, 3, 4, 5, 6, 7 , 8 and 9.
Comparative GABA antagonist compounds that did not show antiflukicidal effect against Fasciola hepatica NEJs (showing a phenotypic score below 3) are shown in Table 2 below:
References
[1] Edwards J, Brown M, Peak E, Bartholomew B, Nash RJ, Hoffmann KF. The Diterpenoid 7-Keto- Sempervirol, Derived from Lycium chinense, Displays Anthelmintic Activity against both Schistosoma mansoni and Fasciola hepatica. PLoS neglected tropical diseases.
2015;9(3):e0003604. Epub 2015/03/15. doi: 10.1371/journal.pntd.0003604. PubMed PMID: 25768432.
Claims
R1 - R5 is H, F, Cl or CF3
X is O or S, preferably 0
- denotes the bond to the carbonyl group for use in the treatment of fasciolosis of mammals.
2. The compound for use according to claim 1 wherein the compound is selected from fluralaner, (S)- fluralaner, afoxolaner, sarolaner, or lotilaner.
3. A compound for use in the treatment of fasciolosis of mammals wherein the compound is tigolaner.
4. The compound for use according any one of claim 1 to 3 wherein the mammal is selected from the group consisting of sheep and cattle.
5. The compound for use according to any one of claims 1 to 4, wherein fasciolosis is treated during autumn, winter, or early spring season.
6. The compound for use according to any one of claims 1 to 3, wherein the fasciolosis is due to an early immature stage liver fluke infection of the mammal by early immature larvae 1 to 6 weeks old.
7. The compound for use according to any one of claims 1 to 3, wherein the fasciolosis is due to an immature stage liver fluke infection of the mammal by immature larvae 6 to 9 weeks old.
8. The compound for use according to any one of claims 1 to 3, wherein the fasciolosis is due to a mature stage liver fluke infection of the mammal by mature flukes >9 weeks old.
9. A composition comprising a compound as defined in any one of claims 1 to 3 and a pharmaceutically acceptable carrier for use in the treatment of fasciolosis of mammals as defined in any one of claims 4 to 8.
10.The composition for use according to claim 9, comprising an additional active ingredient.
11. The composition for use according to any one of claims 9 to 10, wherein the composition is administered orally to the mammal.
12. The composition for use according to any one of claims 9 to 10, wherein the composition is administered subcutaneously to the mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22193586 | 2022-09-02 | ||
EP22193586.9 | 2022-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047241A1 true WO2024047241A1 (en) | 2024-03-07 |
Family
ID=83191797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074068 WO2024047241A1 (en) | 2022-09-02 | 2023-09-01 | Treatment of fasciolosis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047241A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085216A1 (en) | 2004-03-05 | 2005-09-15 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and noxious organism control agent |
WO2007079162A1 (en) | 2005-12-30 | 2007-07-12 | E. I. Du Pont De Nemours And Company | Isoxazolines for controlling invertebrate pests |
WO2009002809A2 (en) | 2007-06-26 | 2008-12-31 | E. I. Du Pont De Nemours And Company | Naphthalene isoxazoline invertebrate pest control agents |
WO2009080250A2 (en) | 2007-12-24 | 2009-07-02 | Syngenta Participations Ag | Insecticidal compounds |
WO2010070068A2 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Organic compounds |
WO2010079077A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
WO2011075591A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Anti parasitic dihydroazole compounds and compositions comprising same |
WO2011124998A1 (en) | 2010-04-08 | 2011-10-13 | Pfizer Inc. | Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides |
-
2023
- 2023-09-01 WO PCT/EP2023/074068 patent/WO2024047241A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085216A1 (en) | 2004-03-05 | 2005-09-15 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and noxious organism control agent |
US20070066617A1 (en) | 2004-03-05 | 2007-03-22 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and pesticide |
WO2007079162A1 (en) | 2005-12-30 | 2007-07-12 | E. I. Du Pont De Nemours And Company | Isoxazolines for controlling invertebrate pests |
WO2009002809A2 (en) | 2007-06-26 | 2008-12-31 | E. I. Du Pont De Nemours And Company | Naphthalene isoxazoline invertebrate pest control agents |
WO2009080250A2 (en) | 2007-12-24 | 2009-07-02 | Syngenta Participations Ag | Insecticidal compounds |
WO2010079077A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
WO2010070068A2 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Organic compounds |
WO2011075591A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Anti parasitic dihydroazole compounds and compositions comprising same |
WO2011124998A1 (en) | 2010-04-08 | 2011-10-13 | Pfizer Inc. | Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides |
Non-Patent Citations (3)
Title |
---|
CASTRO-HERMIDA JOSÉ ANTONIO ET AL: "Current Challenges for Fasciolicide Treatment in Ruminant Livestock", TRENDS IN PARASITOLOGY, ELSEVIER CURRENT TRENDS, GB, vol. 37, no. 5, 15 January 2021 (2021-01-15), pages 430 - 444, XP086536721, ISSN: 1471-4922, [retrieved on 20210115], DOI: 10.1016/J.PT.2020.12.003 * |
EDWARDS JBROWN MPEAK EBARTHOLOMEW BNASH RJHOFFMANN KF: "The Diterpenoid 7-Keto-Sempervirol, Derived from Lycium chinense, Displays Anthelmintic Activity against both Schistosoma mansoni and Fasciola hepatica", PLOS NEGLECTED TROPICAL DISEASES, vol. 9, no. 3, 15 March 2015 (2015-03-15), pages e0003604 |
GENNARO: "Remington: The Science and Practice of Pharmacy", 2000 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11712416B2 (en) | Solid oral pharmaceutical compositions for isoxazoline compounds | |
US11896594B2 (en) | Palatable antiparasitic formulations | |
RU2673723C1 (en) | Antiparasitic use of isoxazoline compounds | |
WO2024047241A1 (en) | Treatment of fasciolosis | |
JPH06211792A (en) | Systemic extermination of parasite | |
JP2003514834A (en) | Combination of N-phenyl-N'-benzoylurea derivative and nectin compound for controlling parasites | |
JP5981430B2 (en) | Composition for treating Hartworm infection | |
CN113134008B (en) | Ivermectin praziquantel chewable tablet for pets and preparation method thereof | |
AU2005336458B2 (en) | Anthelmintic formulations | |
Taylor | Use of anthelmintics in sheep | |
EA001623B1 (en) | Acyl urea compounds for the treatment of coccidiodomycosis in warm-blooded animals | |
US11903962B1 (en) | Isoxazoline complexes and compositions thereof | |
RU2773154C1 (en) | Antiparasitic compounds with an appealing flavour | |
EP4076447B1 (en) | Parasite control in ruminants | |
Yadav et al. | Medical management of Dipylidium caninum infected female cat: A case report | |
Herdiana et al. | Drug Delivery System in Feline Yedi Herdiana1, 2, Gofarana Wilar2, 3, Ferry Ferdiansyah Sofian4, Annisa Dyah Pitaloka4, Yasinta Nurhijriah4, Rayhan Zarra Safira4, Annisa Siti Salsabila4, Maziyatunisa Z4 | |
RU2772279C2 (en) | Solid pharmaceutical compositions for oral administration based on isooxazoline compounds | |
Miller | The epidemiology and control of nematode parasites of ruminants in Texas | |
BORAY et al. | Liver fluke–an essay–by Dr Joe Boray–comments/clarification | |
Jordan | Rabbit Medicine | |
JPS5817444B2 (en) | anticoccidial agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764889 Country of ref document: EP Kind code of ref document: A1 |